# Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma

> **NCT00143871** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 35 (—)

## Conditions studied

- Lymphoma, Non-Hodgkin's

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00143871
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2006-12
- **Final completion:** 2007-01
- **Target enrollment:** 35 (—)
- **Last updated:** 2012-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00143871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00143871, "Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00143871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*